Management of regorafenib-related toxicities: a review

Regorafenib (Stivarga, BAY 73-4506; Bayer Pharma AG, Berlin, Germany) is an oral multikinase inhibitor that targets the angiogenic tumor microenvironment and oncogenic kinases including vascular endothelial growth factor receptor 2 (VEGFR2), VEGFR1, VEGFR3, fibroblast growth factor receptor 1 (FGFR1...

Full description

Saved in:
Bibliographic Details
Published in:Therapeutic Advances in Gastroenterology 2015-09, Vol.8 (5), p.285-297
Main Authors: Krishnamoorthy, Saravanan K., Relias, Valerie, Sebastian, Sunit, Jayaraman, Vijay, Saif, Muhammad Wasif
Format: Article
Language:English
Subjects:
Reviews
Citations: Items that this one cites
Items that cite this one
Online Access:Request full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c566t-def3a5153fce09de036c96295e860e2f8a370a4ef5e6ffd645d9e987454efd2a3
cites cdi_FETCH-LOGICAL-c566t-def3a5153fce09de036c96295e860e2f8a370a4ef5e6ffd645d9e987454efd2a3
container_end_page 297
container_issue 5
container_start_page 285
container_title Therapeutic Advances in Gastroenterology
container_volume 8
creator Krishnamoorthy, Saravanan K.
Relias, Valerie
Sebastian, Sunit
Jayaraman, Vijay
Saif, Muhammad Wasif
description Regorafenib (Stivarga, BAY 73-4506; Bayer Pharma AG, Berlin, Germany) is an oral multikinase inhibitor that targets the angiogenic tumor microenvironment and oncogenic kinases including vascular endothelial growth factor receptor 2 (VEGFR2), VEGFR1, VEGFR3, fibroblast growth factor receptor 1 (FGFR1), RAF, KIT, RET and BRAF. Its antiangiogenic effect is greater than that of its related drug, sorafenib. Regorafenib has been approved by the US Food and Drug Administration (FDA) for the treatment of metastatic colorectal cancer (mCRC) in patients who have failed treatment with fluoropyrimidine, oxaliplatin and irinotecan based chemotherapy, an anti-VEGF therapy and, if KRAS wild type, an anti-EGFR therapy. The FDA based this approval on data from the CORRECT trial, which showed the efficacy of regorafenib compared with placebo. The most common grade 3–4 adverse reactions with the drug are hand foot skin reactions (HFSR), diarrhea, hypertension and fatigue. This review discusses the efficacy data, and the incidence and management of regorafenib’s toxicities.
doi_str_mv 10.1177/1756283X15580743
format article
fullrecord <record><control><sourceid>proquest_AFRWT</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_db517b3a7e6343cfa515087fd32c1d07</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sage_id>10.1177_1756283X15580743</sage_id><doaj_id>oai_doaj_org_article_db517b3a7e6343cfa515087fd32c1d07</doaj_id><sourcerecordid>1709395661</sourcerecordid><originalsourceid>FETCH-LOGICAL-c566t-def3a5153fce09de036c96295e860e2f8a370a4ef5e6ffd645d9e987454efd2a3</originalsourceid><addsrcrecordid>eNp1kc1PGzEQxa0KVGjae08oRy4L_ljbaw6VEGopEogLSNysiT1OHW3W1N4A_e9xCI1KJU62nt_8xjOPkK-MHjGm9THTUvFO3DEpO6pb8YHsr6WGd223s72Luz3yqZQFpYprYT6SPa4E14aZfaKuYIA5LnEYpylMM85ThoBDnDUZexjRT8f0FF0cI5aTKVTHQ8THz2Q3QF_wy-s5Ibc_vt-c_Wwur88vzk4vGyeVGhuPQYBkUgSH1HikQjmjuJHYKYo8dCA0hRaDRBWCV630Bk2nW1k1z0FMyMWG6xMs7H2OS8h_bIJoX4SU5xbyGF2P1s8k0zMBGpVohQvrvrTTwQvumKe6sr5tWPer2RK9qyNn6N9A374M8ZedpwfbSkHbusYJOXwF5PR7hWW0y1gc9j0MmFbFMk2NMHVwVq10Y3U5lZIxbNswatfR2f-jqyUH_35vW_A3q2poNoZSA7OLtMpDXf37wGc_YKHX</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1709395661</pqid></control><display><type>article</type><title>Management of regorafenib-related toxicities: a review</title><source>Sage Journals GOLD Open Access 2024</source><creator>Krishnamoorthy, Saravanan K. ; Relias, Valerie ; Sebastian, Sunit ; Jayaraman, Vijay ; Saif, Muhammad Wasif</creator><creatorcontrib>Krishnamoorthy, Saravanan K. ; Relias, Valerie ; Sebastian, Sunit ; Jayaraman, Vijay ; Saif, Muhammad Wasif</creatorcontrib><description>Regorafenib (Stivarga, BAY 73-4506; Bayer Pharma AG, Berlin, Germany) is an oral multikinase inhibitor that targets the angiogenic tumor microenvironment and oncogenic kinases including vascular endothelial growth factor receptor 2 (VEGFR2), VEGFR1, VEGFR3, fibroblast growth factor receptor 1 (FGFR1), RAF, KIT, RET and BRAF. Its antiangiogenic effect is greater than that of its related drug, sorafenib. Regorafenib has been approved by the US Food and Drug Administration (FDA) for the treatment of metastatic colorectal cancer (mCRC) in patients who have failed treatment with fluoropyrimidine, oxaliplatin and irinotecan based chemotherapy, an anti-VEGF therapy and, if KRAS wild type, an anti-EGFR therapy. The FDA based this approval on data from the CORRECT trial, which showed the efficacy of regorafenib compared with placebo. The most common grade 3–4 adverse reactions with the drug are hand foot skin reactions (HFSR), diarrhea, hypertension and fatigue. This review discusses the efficacy data, and the incidence and management of regorafenib’s toxicities.</description><identifier>ISSN: 1756-283X</identifier><identifier>ISSN: 1756-2848</identifier><identifier>EISSN: 1756-2848</identifier><identifier>DOI: 10.1177/1756283X15580743</identifier><identifier>PMID: 26327919</identifier><language>eng</language><publisher>London, England: SAGE Publications</publisher><subject>Reviews</subject><ispartof>Therapeutic Advances in Gastroenterology, 2015-09, Vol.8 (5), p.285-297</ispartof><rights>The Author(s), 2015</rights><rights>The Author(s), 2015 2015 SAGE Publications</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c566t-def3a5153fce09de036c96295e860e2f8a370a4ef5e6ffd645d9e987454efd2a3</citedby><cites>FETCH-LOGICAL-c566t-def3a5153fce09de036c96295e860e2f8a370a4ef5e6ffd645d9e987454efd2a3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4530428/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4530428/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,313,314,727,780,784,792,885,21966,27853,27922,27924,27925,44945,45333,53791,53793</link.rule.ids><linktorsrc>$$Uhttps://journals.sagepub.com/doi/full/10.1177/1756283X15580743?utm_source=summon&amp;utm_medium=discovery-provider$$EView_record_in_SAGE_Publications$$FView_record_in_$$GSAGE_Publications</linktorsrc><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26327919$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Krishnamoorthy, Saravanan K.</creatorcontrib><creatorcontrib>Relias, Valerie</creatorcontrib><creatorcontrib>Sebastian, Sunit</creatorcontrib><creatorcontrib>Jayaraman, Vijay</creatorcontrib><creatorcontrib>Saif, Muhammad Wasif</creatorcontrib><title>Management of regorafenib-related toxicities: a review</title><title>Therapeutic Advances in Gastroenterology</title><addtitle>Therap Adv Gastroenterol</addtitle><description>Regorafenib (Stivarga, BAY 73-4506; Bayer Pharma AG, Berlin, Germany) is an oral multikinase inhibitor that targets the angiogenic tumor microenvironment and oncogenic kinases including vascular endothelial growth factor receptor 2 (VEGFR2), VEGFR1, VEGFR3, fibroblast growth factor receptor 1 (FGFR1), RAF, KIT, RET and BRAF. Its antiangiogenic effect is greater than that of its related drug, sorafenib. Regorafenib has been approved by the US Food and Drug Administration (FDA) for the treatment of metastatic colorectal cancer (mCRC) in patients who have failed treatment with fluoropyrimidine, oxaliplatin and irinotecan based chemotherapy, an anti-VEGF therapy and, if KRAS wild type, an anti-EGFR therapy. The FDA based this approval on data from the CORRECT trial, which showed the efficacy of regorafenib compared with placebo. The most common grade 3–4 adverse reactions with the drug are hand foot skin reactions (HFSR), diarrhea, hypertension and fatigue. This review discusses the efficacy data, and the incidence and management of regorafenib’s toxicities.</description><subject>Reviews</subject><issn>1756-283X</issn><issn>1756-2848</issn><issn>1756-2848</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>DOA</sourceid><recordid>eNp1kc1PGzEQxa0KVGjae08oRy4L_ljbaw6VEGopEogLSNysiT1OHW3W1N4A_e9xCI1KJU62nt_8xjOPkK-MHjGm9THTUvFO3DEpO6pb8YHsr6WGd223s72Luz3yqZQFpYprYT6SPa4E14aZfaKuYIA5LnEYpylMM85ThoBDnDUZexjRT8f0FF0cI5aTKVTHQ8THz2Q3QF_wy-s5Ibc_vt-c_Wwur88vzk4vGyeVGhuPQYBkUgSH1HikQjmjuJHYKYo8dCA0hRaDRBWCV630Bk2nW1k1z0FMyMWG6xMs7H2OS8h_bIJoX4SU5xbyGF2P1s8k0zMBGpVohQvrvrTTwQvumKe6sr5tWPer2RK9qyNn6N9A374M8ZedpwfbSkHbusYJOXwF5PR7hWW0y1gc9j0MmFbFMk2NMHVwVq10Y3U5lZIxbNswatfR2f-jqyUH_35vW_A3q2poNoZSA7OLtMpDXf37wGc_YKHX</recordid><startdate>20150901</startdate><enddate>20150901</enddate><creator>Krishnamoorthy, Saravanan K.</creator><creator>Relias, Valerie</creator><creator>Sebastian, Sunit</creator><creator>Jayaraman, Vijay</creator><creator>Saif, Muhammad Wasif</creator><general>SAGE Publications</general><general>SAGE Publishing</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20150901</creationdate><title>Management of regorafenib-related toxicities: a review</title><author>Krishnamoorthy, Saravanan K. ; Relias, Valerie ; Sebastian, Sunit ; Jayaraman, Vijay ; Saif, Muhammad Wasif</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c566t-def3a5153fce09de036c96295e860e2f8a370a4ef5e6ffd645d9e987454efd2a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Reviews</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Krishnamoorthy, Saravanan K.</creatorcontrib><creatorcontrib>Relias, Valerie</creatorcontrib><creatorcontrib>Sebastian, Sunit</creatorcontrib><creatorcontrib>Jayaraman, Vijay</creatorcontrib><creatorcontrib>Saif, Muhammad Wasif</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Therapeutic Advances in Gastroenterology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>Krishnamoorthy, Saravanan K.</au><au>Relias, Valerie</au><au>Sebastian, Sunit</au><au>Jayaraman, Vijay</au><au>Saif, Muhammad Wasif</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Management of regorafenib-related toxicities: a review</atitle><jtitle>Therapeutic Advances in Gastroenterology</jtitle><addtitle>Therap Adv Gastroenterol</addtitle><date>2015-09-01</date><risdate>2015</risdate><volume>8</volume><issue>5</issue><spage>285</spage><epage>297</epage><pages>285-297</pages><issn>1756-283X</issn><issn>1756-2848</issn><eissn>1756-2848</eissn><abstract>Regorafenib (Stivarga, BAY 73-4506; Bayer Pharma AG, Berlin, Germany) is an oral multikinase inhibitor that targets the angiogenic tumor microenvironment and oncogenic kinases including vascular endothelial growth factor receptor 2 (VEGFR2), VEGFR1, VEGFR3, fibroblast growth factor receptor 1 (FGFR1), RAF, KIT, RET and BRAF. Its antiangiogenic effect is greater than that of its related drug, sorafenib. Regorafenib has been approved by the US Food and Drug Administration (FDA) for the treatment of metastatic colorectal cancer (mCRC) in patients who have failed treatment with fluoropyrimidine, oxaliplatin and irinotecan based chemotherapy, an anti-VEGF therapy and, if KRAS wild type, an anti-EGFR therapy. The FDA based this approval on data from the CORRECT trial, which showed the efficacy of regorafenib compared with placebo. The most common grade 3–4 adverse reactions with the drug are hand foot skin reactions (HFSR), diarrhea, hypertension and fatigue. This review discusses the efficacy data, and the incidence and management of regorafenib’s toxicities.</abstract><cop>London, England</cop><pub>SAGE Publications</pub><pmid>26327919</pmid><doi>10.1177/1756283X15580743</doi><tpages>13</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext_linktorsrc
identifier ISSN: 1756-283X
ispartof Therapeutic Advances in Gastroenterology, 2015-09, Vol.8 (5), p.285-297
issn 1756-283X
1756-2848
1756-2848
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_db517b3a7e6343cfa515087fd32c1d07
source Sage Journals GOLD Open Access 2024
subjects Reviews
title Management of regorafenib-related toxicities: a review
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-01T17%3A05%3A49IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_AFRWT&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Management%20of%20regorafenib-related%20toxicities:%20a%20review&rft.jtitle=Therapeutic%20Advances%20in%20Gastroenterology&rft.au=Krishnamoorthy,%20Saravanan%20K.&rft.date=2015-09-01&rft.volume=8&rft.issue=5&rft.spage=285&rft.epage=297&rft.pages=285-297&rft.issn=1756-283X&rft.eissn=1756-2848&rft_id=info:doi/10.1177/1756283X15580743&rft_dat=%3Cproquest_AFRWT%3E1709395661%3C/proquest_AFRWT%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c566t-def3a5153fce09de036c96295e860e2f8a370a4ef5e6ffd645d9e987454efd2a3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1709395661&rft_id=info:pmid/26327919&rft_sage_id=10.1177_1756283X15580743&rfr_iscdi=true